摘要
目的:观察缬沙坦对心房颤动的治疗效果并探讨其作用机制。方法:选择无器质性心脏疾病的阵发性房颤(PAF)患者80例,均分为两组,缬沙坦组:使用缬沙坦口服治疗;对照组,不使用缬沙坦治疗,观察6个月。记录治疗前后两组房颤的发作频率及平均每次持续时间,并检测两组患者治疗前、后血浆基质金属蛋白酶9(MMP-9)的变化。结果:治疗6个月后,缬沙坦组患者房颤发作的频率[(7±2.3)次/周∶(11±3.6)次/周],平均持续时间[(102±31)min/次∶(131±44)min/次],MMP-9[(188.25±55.47)ng/ml∶(281.13±58.21)ng/ml]的含量均显著低于治疗前,也显著低于对照组[(14±6.7)次/周,(153±62)min/次,(261.72±52.94)ng/ml],P均<0.01。结论:缬沙坦治疗阵发性房颤有一定作用,而降低基质金属蛋白酶9的浓度可能是其治疗的机制之一。
Objective:To investigate the effect of valsartan on paroxysmal atrial fibrillation(PAF) and its mechanism.Methods:A total of 80 PAF and free from organic heart diseases patients were involved in the study.The patients were randomly average divided into two groups:valsartan group(in which patients were treated with valsartan)and control group(in which patients did not receive valsartan).All patients were followed up for 6 month.The frequency of AF episode and mean time of onset of AF were recorded before and after treatment.Serum levels of matrix metalloproteinase-9(MMP-9) of the two groups were detected before and after treatment.Results:After 6 months,compared with before treatment the frequency of AF episode [(7±2.3) times /week vs.(11±3.6) times /week],mean time of onset of AF [(102±31)min/ time vs.(131±44) min/ time],MMP-9[(188.25±55.47)ng/ml vs.(281.13±58.21) ng/ml] significantly decreased in valsartan group,and also significantly decreased than those of control group [(14±6.7) times /week,(153±62) min/ time,(261.72±52.94) ng/ml],P0.01 all.Conclusion:Valsartan is effective for paroxysmal atrial fibrillation and decline of serum matrix metalloprotein-9 level may be one of its mechanisms.
出处
《心血管康复医学杂志》
CAS
2011年第1期73-75,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心房颤动
缬沙坦
明胶酶B
Atrial fibrillation
Valsartan
Gelatinase B